Prostate Cancer Research Program Impact Award – The overall goal of the FY10 PCRP is to find and fund innovative, high-impact research that will eliminate death and suffering from prostate cancer. Specifically, the PCRP seeks to: 1) Support innovative high-risk, high-gain research with potential near-term impact; 2) Sponsor multidisciplinary synergistic research; 3) Fund translational studies to promote the fluid transition of knowledge between bedside and bench; 4) Invest in research on patient survivorship (quality of life); 5) Foster the next generation of prostate cancer investigators through mentored research; and 6) Promote research into prostate cancer health disparities. The overarching goals of the FY10 program are aimed towards eliminating death and suffering from prostate cancer. All applications for the PCRP Impact Award should address at least one of these overarching challenges: 1) Develop effective treatments for advanced prostate cancer; 2) Distinguish lethal from indolent disease. Applications for the PCRP Impact Award should also address at least one of the following FY10 PCRP focus areas: 1) Biomarkers: Discovery and validation of biomarkers for the detection, prognosis, and progression of prostate cancer; 2) Genetics: Understanding the genetics and epigenetics responsible for susceptibility, disease progression, and treatment outcomes for clinically significant prostate cancer; 3) Imaging: Development of new imaging technology for the detection and prognosis of prostate cancer, including progression to systemic disease; 4) Survivorship: Studies on the impacts of treatment, nutrition, metabolism, and exercise on the well being of prostate cancer patients and their families; 5) Therapy: Identification of new targets, pathways, and therapeutic modalities or molecules for the treatment of prostate cancer; 6) Tumor Biology: Understanding the heterogeneity and microenvironment for the prognosis and progression of prostate cancer. Eligibility: Applicants must be independent investigators at or above the level of Assistant Professor (or equivalent). The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $750,000 in direct costs. Closing Date: April 19, 2010.
Posted Date: February 2, 2010
Funding Opportunity Number: W81XWH-10-PCRP-IA
————————————————————————————-
DoD Peer Reviewed Medical Clinical Trial Award – The vision of the FY10 PRMRP is to identify and fund the best medical research to protect and support war fighters, veterans and all beneficiaries and to eradicate diseases that impact these populations. The PRMRP seeks proposals in laboratory, clinical, behavioral, and epidemiologic research as well as public health and policy; environmental sciences; nursing; occupational health; alternative therapies; ethics; economics; and strategic research, such as studies designed to shape the development of or to validate clinical policy or guidance. Interdisciplinary and integrative health approaches are welcomed. This award is intended to support the rapid implementation of clinical trials of interventions with the potential to have a significant impact on a disease or condition addressed in at least one of the congressionally directed FY10 PRMRP topic areas. All studies must be responsive to the health care needs of the Armed Forces, their family members, and/or the U.S. veteran population, and may address prevention, detection, diagnosis, treatment, and/or quality of life. All applications must specifically and clearly address the military relevance of the proposed research. Collaboration with military and/or U.S. Department of Veterans Affairs (VA) researchers and/or clinicians is encouraged; however, the use of military populations is not a prerequisite. Proposals recruiting civilian populations as an alternative are strongly recommended. PIs at or above the level of Assistant Professor (or equivalent) are eligible to submit applications. The maximum period of performance is 5 years. The maximum allowable funding for the entire period of performance is $2.2M in direct costs. Closing Date: May 13, 2010.
Posted Date: January 29, 2010
Funding Opportunity Number: W81XWH-10-PRMRP-CTA
————————————————————————————-
DoD Peer Reviewed Medical Investigator-Initiated Research Award – This award mechanism is intended to support studies that will make an important contribution toward understanding mechanisms of initiation, or progression of and/or improving patient care for a disease or a condition related to at least one of the congressionally directed FY10 PRMRP topic areas. Research proposals should be responsive to the health care needs of the Armed Forces, their family members, and/or the U.S. veteran population. All applications must specifically and clearly address the military relevance of the proposed research. Collaboration with military and/or US Department of Veterans Affairs (VA) researchers and/or clinicians is encouraged. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician’s first-hand knowledge of patients and anecdotal data. Applications must include data relevant to the FY10 PRMRP topic area(s) addressed that support the rationale for the proposed study. These data may be unpublished and/or from the published literature. The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $725,000 in direct costs. PIs at or above the level of Assistant Professor (or equivalent) are eligible to submit applications. Closing Date: August 5, 2010.
Posted Date: January 29, 2010
Funding Opportunity Number: W81XWH-10-PRMRP-IIRA
————————————————————————————-
DoD Peer Reviewed Medical Technology/Therapeutic Development Award – This award is product-driven and is intended to provide support for the translation of promising preclinical findings into products for clinical applications in at least one of the congressionally directed FY10 PRMRP topic areas. Products in development should be responsive to the health care needs of the Armed Forces, their family members, and/or the U.S. veteran population. All applications must specifically and clearly address the military relevance of the proposed research. Collaboration with military and/or U.S Department of Veterans Affairs (VA) researchers and/or clinicians is encouraged. The product(s) to be developed may be pharmacologic agents (drugs or biologicals), devices, and/or clinical guidance. The Principal Investigator (PI) must provide a transition plan (including potential funding and resources) showing how the product will progress to clinical trials and/or delivery to the military or civilian market after the completion of the PRMRP award. Applications must include data relevant to the FY10 PRMRP topic area(s) addressed that support the rationale for the proposed study. These data may be unpublished and/or from the published literature. PIs at or above the level of Assistant Professor (or equivalent) are eligible to submit applications. The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $1.7M in direct costs. Closing Date: May 13, 2010.
Posted Date: January 29, 2010
Funding Opportunity Number: W81XWH-10-PRMRP-TTDA
————————————————————————————-
DoD Breast Cancer Postdoctoral Fellowship Award – The Postdoctoral Fellowship Award supports exceptionally talented recent medical or other doctoral graduates performing innovative, high-impact breast cancer research during their postdoctoral training, and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research. Candidates for this award should exhibit a strong desire to pursue a career in breast cancer research. While the PI is not required to have previous experience in breast cancer research, this proposal must focus on breast cancer research. Proposals must emphasize the PI’s high potential for success in becoming an independent breast cancer researcher based on his/her qualifications, achievements, and letters of recommendations. Proposals must provide details on the suitability of the PI’s overall training plan and research project for attaining the goals of this mechanism. In addition, proposals must elaborate on the quality of the training environment in which the candidate will work, provide details on the training program and describe how this training will facilitate the candidate’s career development as an independent, innovative breast cancer researcher. A multidisciplinary research approach to breast cancer is highly encouraged but not required; however, if there are multi-disciplinary aspects to the training, they should be clearly outlined in the proposal. The maximum period of performance is 3 years. The maximum allowable funding for the entire period of performance is $300,000 in direct costs. Closing Date: April 7, 2010.
Posted Date: January 29, 2010
Funding Opportunity Number: W81XWH-10-BCRP-POSTDOC
————————————————————————————-
DoD Breast Cancer Idea Award – The Idea Award is designed to promote new ideas that are still in the early stages of development and have the potential to yield highly impactful data and new avenues of investigation. This mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will accelerate the eradication of breast cancer. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. The BCRP seeks applications from all areas of basic, translational, clinical, behavioral, and epidemiological research. Presentation of preliminary data is not consistent with the intent of the Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data. Innovation and Impact are the most important aspects of the Idea Award. Expected Number of Awards: 75; Estimated Total Program Funding: $46,300,000. Closing Date: May 5, 2010.
Posted Date: January 29, 2010
Funding Opportunity Number: W81XWH-10-BCRP-IDEA
————————————————————————————-
DoD Breast Cancer Multi-Team Award – The BCRP Multi-Team Award supports the creation of a collaborative research project among three teams, each led by a Principal Investigator (PI) with a history of creativity and innovation, to focus on a critical area of breast cancer. Research proposed under the Multi-Team Award must focus on a question of significant importance to breast cancer that has been inadequately addressed, or for which there may be an absence of an established paradigm or technical framework. The research question should address overarching issues that have broad implications for the disease and risk management (e.g., risk factors, dormancy) and not focus merely on the study of specific pathways or genes. Clinical research (may include clinical trials) must be included as part of the proposed work. The Multi-Team Award supports the collaborative efforts of three teams consisting of scientists and consumer advocates. Collectively, the members of the teams should represent the appropriate DOD FY10 Breast Cancer Multi-Team Award 3 diversity of expertise necessary for addressing the research question. Participating institutions must be willing to resolve potential intellectual and material property issues and remove institutional barriers to achieving high levels of cooperation. The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $4.5M in direct costs. Closing Date: June 23, 2010.
Posted Date: January 29, 2010
Funding Opportunity Number: W81XWH-10-BCRP-MTA
————————————————————————————-
DoD Breast Cancer Transformative Vision Award – The most important aspect of the Transformative Vision Award is the articulation of the vision for a new approach to significantly impact the prevention or treatment of breast cancer. The final impact may be near-term or long-term, but the success of the vision must be transformative on breast cancer. A careful presentation of the state-of-the-art, and how the vision will transform this state, must be described. The vision must be supported by a detailed plan that identifies critical milestones and clearly outlines the innovations and technical solutions that will be implemented to accomplish the milestones. The scope of the research effort may include a broad spectrum of research spanning from basic to clinical studies, with the end result leading to a revolutionary impact on an area of paramount importance in breast cancer prevention or treatment. The Transformative Vision Award will be supported in two phases. Phase I will enable the team to lay the groundwork for the research project and to test the basic concepts of the vision. Phase II will allow the expansion of the project to proceed to accomplishment of the vision. The maximum period of performance is 5 years. The maximum allowable funding for the entire period of performance is $12M in direct costs. Closing Date: July 23, 2010.
Posted Date: January 29, 2010
Funding Opportunity Number: W81XWH-10-BCRP-TVA
————————————————————————————-
DoD Breast Cancer Inter-Institutional Training Award – The overarching goal of this award mechanism is to establish the foundations for breast cancer research programs at academic institutions where they currently do not exist. This will be accomplished through focused mentoring and training of two or more faculty-level investigators who have limited or no experience in breast cancer research, participating in research collaborations with experienced breast cancer investigators. The Principal Investigator (PI) and co-PIs must indicate a commitment to becoming competitive breast cancer researchers and to the establishment of a breast cancer research program at their institution. This award provides mentorship and training at an institutional level by supporting collaborations between: 1) Multiple investigators at an academic institution that does not have an established breast cancer research program; and 2) At least one experienced breast cancer researcher (Primary Collaborating Mentor) at a different research institution, which has a well-established breast cancer research program. The PI and co-PI(s) each must have a doctoral degree (Ph.D., M.D., or equivalent) and hold a faculty position (Assistant Professor or higher) at an academic institution without a breast cancer program. The applicant institution must have received no more than $500,000 in aggregate during the past three calendar years (2006-2009) in non-mentored federal funding for breast cancer research. The maximum period of performance is 4 years. The maximum allowable funding for the entire period of performance is $1M in direct costs. Closing Date: June 23, 2010.
Posted Date: January 29, 2010
Funding Opportunity Number: W81XWH-10-BCRP-IITA